NDAN/ASOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
DEFENCATH (taurolidine and heparin) by CorMedix. Approved for anti-coagulant [epc]. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEFENCATH is a taurolidine and heparin solution approved in November 2023 for use as an anti-coagulant in extracorporeal circuits (EPC), such as dialysis and cardiopulmonary bypass systems. The combination leverages taurolidine's antimicrobial properties with heparin's anticoagulant activity to prevent clotting in medical device circuits. This dual-mechanism approach addresses a niche but critical need in specialized hospital and dialysis settings.
Growth15.6 years to LOE
As a newly approved product in the growth phase with limited competitive pressure, the commercial team is likely expanding to build market awareness and establish relationships with dialysis centers and hospital systems.
Mechanism of Action
Pharmacologic Class:
Anti-coagulant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Started May 2025
200 enrolled
Central Line Associated Blood Stream Infections (CLABSI)
Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
Catheter-related Bloodstream Infection
Career Relevance
DEFENCATH represents an early-stage growth opportunity in a specialized, high-value niche market (dialysis and cardiac surgery), attracting professionals focused on building market presence and establishing hospital/dialysis center relationships. Roles are heavily weighted toward commercial execution, with strong demand for field sales, account management, and medical affairs professionals who can educate and influence nephrologists, cardiac surgeons, and dialysis operators.
Worked on DEFENCATH at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.